

1 COOLEY LLP
MICHAEL ATTANASIO (151529)
2 (mattanasio@cooley.com)
BARRETT J. ANDERSON (318539)
3 (banderson@cooley.com)
CRAIG E. TENBROECK (287848)
4 (ctenbroeck@cooley.com)
JASMIN F. MOTLAGH (311639)
5 (jmotlagh@cooley.com)
DYLAN K. SCOTT (332796)
6 (dscott@cooley.com)
RACHAEL M. HELLER (335636)
7 (rheller@cooley.com)
4401 Eastgate Mall
8 San Diego, CA 92121-1909
Telephone: (858) 550-6000
9 Facsimile: (858) 550-6420

10 *Attorneys for Plaintiff and Counter-Defendant*
11 *ChromaDex, Inc.*

12 *Counsel continued on following page*

13 **UNITED STATES DISTRICT COURT**
14 **CENTRAL DISTRICT OF CALIFORNIA**
15 **(SOUTHERN DIVISION)**

17 ChromaDex, Inc.,
18 Plaintiff,
19 v.
20 Elysium Health, Inc., and Mark Morris,
21 Defendants.

22 Elysium Health, Inc.,
23 Counterclaimant,
24 v.
25 ChromaDex, Inc.,
26 Counter-Defendant.
27

Case No. 8:16-cv-2277-CJC (DFMx)

JOINT EXHIBIT LIST

Judge: Hon. Cormac J. Carney
Courtroom: 9B

Trial: September 21, 2021
Pretrial Conf.: September 13, 2021

1 COVINGTON & BURLING LLP
2 MITCHELL A. KAMIN (202788)
3 (mkamin@cov.com)
4 1999 Avenue of the Stars, Suite 3500
5 Los Angeles, CA 90067-4643
6 Telephone: (424) 332-4800
7 Facsimile: (424) 332-4749

8 COVINGTON & BURLING LLP
9 PHILIP A. IRWIN (admitted *pro hac vice*)
10 (pirwin@cov.com)
11 620 Eighth Avenue
12 New York, NY 10018-1405
13 Telephone: (212) 841-1000

14 LTL ATTORNEYS LLP
15 JOE H. TUFFAHA (253723)
16 (joe.tuffaha@ltlattorneys.com)
17 PRASHANTH CHENNAKESAVAN (284022)
18 (prashanth.chennakesavan@ltlattorneys.com)
19 300 South Grand Avenue, 14th Floor
20 Los Angeles, CA 90071
21 Telephone: (213) 612-8900
22 Facsimile: (213) 612-3773

23 *Attorneys for Plaintiff and Counter-Defendant*
24 *ChromaDex, Inc.*
25
26
27
28

1 Pursuant to the Court's November 18, 2020 Order (Dkt. 452), Local Rule 16-6.1,
2 and paragraph 5 of the Court's Standing Order Regarding Settlement Procedures, Pre-
3 trial Conference and Trial, Plaintiff and Counter-Defendant ChromaDex, Inc.,
4 Defendant and Counterclaimant Elysium Health, Inc., and Defendant Mark Morris,
5 hereby submit the following Joint Exhibit List.

6 Dated: September 3, 2021

7 COOLEY LLP
8 MICHAEL A. ATTANASIO (151529)
9 BARRETT J. ANDERSON (318539)
10 CRAIG E. TENBROECK (287848)
11 JASMIN F. MOTLAGH (311639)
12 DYLAN K. SCOTT (332796)
13 RACHAEL M. HELLER (335636)

14 */s/ Michael A. Attanasio*

15

Michael A. Attanasio (151529)

16 *Attorneys for Plaintiff and Counter-Defendant*
17 *ChromaDex, Inc.*

18 *The filer, Michael A. Attanasio, attests that the*
19 *other signatory listed, on whose behalf the*
20 *filing is submitted, concurs in the filing's*
21 *content and has authorized the filing.*

22 Dated: September 3, 2021

23 COHEN WILLIAMS LLP
24 MARC S. WILLIAMS (198913)
25 REUVEN L. COHEN (231915)
26 BRITTANY LANE (323440)

27 KAPLAN HECKER & FINK LLP
28 JOHN C. QUINN (*pro hac vice*)

/s/ Marc S. Williams

Marc S. Williams (198913)

Attorneys for Defendant and Counterclaimant
Elysium Health, Inc. and
Defendant Mark Morris

JOINT EXHIBIT LIST

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
1	PDF titled "Supply Agreement between ChromaDex and Elysium"		
2	ChromaDex and Elysium's pTeroPure Supply Agreement		
3	Receipt & Acknowledgement of Employee Handbook (Employer Copy)		
4	ChromaDex, Inc. Confidentiality and Non-Solicitation Agreement for Mark Morris		
5	Text Messages		
6	Text Messages		
7	Text Messages		
8	Text Messages		
9	Text Messages		
10	Text Messages		
11	Text Messages		
12	Text Messages		
13	SEC Form 8-K filed by ChromaDex, dated July 9, 2013		
14	License agreement with Thorne		
15	9/10/13 email from E. Marcotulli to F. Jaksch		
16	Email with attachment from B. Prag to F. Jaksch		
17	Email with attachment from E. Marcotulli to J. Jaksch, Prag, D. Alminana, L. Guarente		
18	Email from F. Jaksch to E. Marcotulli, D. Alminana, B. Prag		
19	Email from F. Jaksch to E. Marcotulli, D. Alminana, B. Prag and L. Guarente		
20	PDF titled "Nicotinamide Riboside Chloride by HPLC"		
21	Email from D. Alminana to E. Marcotulli and F. Jaksch		
22	2-3-2014-Trademark License and Royalty Agreement between Elysium Health and ChromaDex, Inc.		
23	Trademark License and Royalty Agreement		
24	Elysium purchase orders and ChromaDex invoices		
25	Email with attachments from C. Villalobos to D. Alminana, E. Marcotulli, F. Jaksch and M. Morris		
26*	6/11/14 email from L. Guarente to F. Jaksch		
27	PDF titled "ChromaDex - Niagen - Full"		
28	Email with attachments from C. Villalobos to M. Morris		
29	Email from C. Villalobos to M. Morris and A. Shargh		
30*	SEC Form 8-K filed by ChromaDex Corporation, dated July 9, 2015		
31	Email with attachments from S. Zhang to D. Alminana and E. Marcotulli		
32	Email from E. Marcotulli to D. Alminana		
33	PDF titled "Mark Morris Paystubs 010116 through 123116"		
34*	1/26/16 email from G. Wang to E. Marcotulli, D. Alminana, L. Guarante		
35	Email from M. Morris to E. Marcotulli and D. Alminana		
36	HR Status Change Form for M. Morris		
37	Email with attachments from J. Robles to A. Shargh		
38	Excel titled "Elysium Health Model.xlsx No PR Expanded Forecast"		
39	Excel titled "Elysium Health Model.xlsx Ordering"		
40	Excel titled "EH-Model thru 2017.xlsx Expanded Forecast"		
41	Email from D. Alminana to S. Zhang		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
42	Email with attachment from M. Morris to D. Alminana, E. Marcotulli		
43	Email from E. Marcotulli to M. Morris and D. Alminana		
44	Email from E. Marcotulli to M. Morris and D. Alminana		
45	Email from D. Alminana to S. Schell and E. Marcotulli		
46	Email from Marcotulli to D. Alminana and L. Guarente		
47	Email with attachment from D. Magida to D. Alminana and E. Marcotulli		
48	Email from M. Morris to M. Morris		
49	Email from M. Morris to D. Alminana and E. Marcotulli		
50	Email from J. Jaksch to D. Alminana, E. Marcotulli		
51	Email from M. Morris to M. Morris		
52	Document titled "NR Favored Pricing.xlsx"		
53	Excel titled "NR Favored Pricing"		
54	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
55	Email from E. Marcotulli to D. Alminana and M. Morris		
56	Email from M. Morris to E. Marcotulli		
57	6-8-2016 E-mail from Mark Morris to Frank Jaksch-Re- Wired Magazine and NR Questions		
58	Email from E. Marcotulli to D. Alminana and M. Morris		
59	PDF titled "Mutual Confidential Disclosure Agreement"		
60	Email from E. Marcotulli to D. Magid and D. Alminana		
61	Email with attachments from M. Morris to M. Morris		
62	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
63	6/20/16 email from E. Marcotulli to L. Guarente, D. Alminana		
64	6/20/16 email from E. Marcotulli to R.Nelson		
65	Email from E. Marcotulli to R. Nelsen		
66	Email with attachment from D. Magida to D. Alminana		
67	Email from M. Morris to D. Alminana		
68	Email from M. Morris to D. Alminana and E. Marcotulli		
69	Email from D. Alminana to E. Marcotulli and M. Morris		
70	Email from D. Alminana to M. Morris, E. Marcotulli		
71	Email from M. Morris to D. Alminana and E. Marcotulli		
72	Email from M. Morris to D. Alminana and E. Marcotulli		
73	Email from M. Morris to D. Alminana, E. Marcotulli		
74	Email with attachment from D. Magida to D. Alminana		
75	Email with attachment from D. Magida to D. Alminana and E. Marcotulli		
76	Email from D. Alminana to M. Morris, E. Marcotulli		
77	6-28-2016-E-mail from Dan Alminana to Frank Jaksch; Troy Rhonemus; Tom Varvaro; Mark Morris, Collene Villalobos-Re- Purchase Orders		
78	Email with attachment from D. Magida to E. Marcotulli and D. Alminana		
79	6-29-2016-E-mail from F.Jaksch to Will Black-Re- FW: Wired Magazine and NR Questions		
80	6-30-2016-E-mail from Frank Jaksch to Dan Alminana-Re- Purchase Orders		
81	6-30-2016-e-mail from Dan Alminana to Frank Jaksch-Re-Purchase Orders		
82	6/29/16 email from D. Alminana to F. Jaksch, T. Rhonemus, T. Varvaro, M. Morris, C. Villalobos, E. Marcotulli		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
83	Email from D. Alminana to F. Jaksch, T. Rhonemus, T. Varvaro, M. Morris, C. Villalobos, E. Marcotulli, W. Black		
84	6-29-2016 email from F. Jaksch to D. Alminana, E. Marcotulli, T. Rhonemus, T. Varvaro, M. Morris, C. Villalobos, W. Black		
85	Email from E. Marcotulli to D. Alminana		
86	Attachment to 7/11/16 from C. Villalobos to D. Alminana, D. Magida		
87*	2/11/16 email from E. Marcotulli to J. Izard, D. Alminana		
88	Email from E. Marcotulli to D. Alminana and M. Morris		
89	Email from E. Marcotulli to M. Morris		
90	Email with attachments from E. Marcotulli to D. Fallow and D. Alminana		
91	Email from Collene Villalobos to Dan Alminana, copying Dan Magida, sent on July 11, 2016		
92	Email from M. Morris to F. Jaksch and T. Rhonemus		
93	Email from Morris to D. Alminana and E. Marcotulli		
94	Document titled "NR Ingredient Sales Data for all customers.xlsx"		
95	Email from M. Morris to ChromaDex		
96	Separation Checklist for Mark Morris		
97	Email with attachments from J. Robles to M. Morris		
98	Email from M. Morris to J. Robles		
99	Email with attachments from J. Robles to D. Doan		
100	ChromaDex employee IT status change report for M. Morris		
101	Email from D. Alminana to E. Marcotulli and M. Morris		
102	Email with attachments from D. Alminana to M. Morris and E. Marcotulli		
103	Elysium employment offer materials to M. morris		
104	Email from D. Alminana to M. Morris and E. Marcotulli		
105	Email from E. Marcotulli to D. Alminana and M. Morris		
106	Excel titled : "NR Ingredient Sales Data for all customers.xlsx"		
107	Word Document titled "NRCI Analytical Method"		
108	Word Document titled "NRCI Process"		
109	Word Document titled "NRCI Specifications"		
110	Excel titled "NRCI Specifications"		
111	Native Excel file (Elysium financial projections)		
112	Native Excel file (Elysium financial projections)		
113	Email from E. Marcotulli to R. Thonemus		
114	7/28/16 email from M. Morris to J. Schock		
115	Email with attachment from Morris to PCI		
116	Document titled "NRCI Analytical Method.docx"		
117	Email with attachment from Morris to PCI		
118	Email from M. Morris to M. Morris		
119	PCI proposal for the Development and Synthesis of Nicotinamide - D- Riboside Chloride Prepared for Elysium		
120	Email with attachments from C. Villalobos to D. Alminana		
121	Email from M. Morris to D. Alminana		
122	Email from W. Black to D. Alminana, E. Marcotulli, F. Jaksch, T. Varvaro and T. Rhonemus		
123	Email from Alminana to Marcotulli re NR Forecast		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
124	Email from E. Marcotulli to D. Givacchini and J. Roberts		
125	Native Excel file (Elysium capitalization)		
126*	8/16/16 email from W. Black to D. Alminana, E. Marcotulli, F. Jaksch, T. Rhonemus, T. Varavaro		
127	Email from W. Black to D. Alminana, E. Marcotulli, T. Rhonemus, F. Jaksch and T. Varavaro		
128	Email from F. Jaksch to D. Alminana, W. Black, E. Marcotulli, T. Rhonemus and T. Varavaro		
129	Email from A. Ilani to E. Marcotulli		
130	ChromaDex PowerPoint Presentation		
131	Document titled "ChromaDex - Pterostilbene.pptx"		
132	Document titled "Niagen - New.pptx"		
133	Document titled "Basis - Science -2.pptx"		
134	Email with attachments from M. Morris to E. Marcotulli, L. Guarente, R. Dellinger and D. Alminana		
135	PCI external meeting minutes		
136*	8/30/16 email from D. Alminana to T. Varavaro, cc: E. Marcotulli, W. Black, F. Jaksch, T. Rhonemus		
137*	8/30/16 email from T. Varavaro to F. Jaksch re Elysium		
138	Email from Morris to L. Guarente, R. Delling, E. Maroctulli and D. Alminana		
139	Email from B. Reynolds to D. Alminana, L. Guarente and E. Marcotulli		
140*	9/22/16 letter from W. Black to G. MacEachern		
141*	9/26/2016 email from W. Black to F. Jaksch, T. Varavaro, T. Rhonemus		
142	Email from D. Magida to E. Marcotulli and D. Alminana		
143	Email with attachment from D. Magida to E. Marcotulli and D. Alminaana		
144	Email from E. Marcotulli to A. Ilani		
145	Email from E. Marcotulli to D. Giovacchini, D. Fialkow, J. Roberts and O. Lew		
146	Email with attachment from D. Magida to K. Kohan		
147	Email with attachments from E. Marcotulli to D. Giovacchini and J. Roberts		
148	Email with attachment from D. Magida to J. Skamarack		
149	Email from D. Alminana to M. Morris		
150	10-31-2016-E-mail from Frank Jaksch to Stephen Block-FW-Call and Royalty Report		
151	Email from D. Magida to D. Alminana		
152	Email with attachments from F. Jaksch to D. Alminana, E. Marcotulli, and S. Block		
153	Email from E. Marcotulli to D. Alminana and L. Guarente		
154	Word document titled "Memo – Q3 2016 Going Concern v2"		
155	PDF titled "Supply Chain Update Presentation"		
156	PCI analytical summary		
157	Email with attachment from D. Magida to J. Moore and M. Morri		
158	Email from M. Morris to E. Marcotulli, D. Alminana, S. Roel Santos and R.Dellinger		
159*	11/19/16 email from F. Jaksch to R. Fried		
160*	11/18/16 email from J. Baxter to S. Allen, F. Jaksch, S. Block, R. Fried, K. Gustafson		
161	Email from M. Morris to M. Morris		
162	Elysium materials on Series B Financing		
163	1-5-2017-E-mail from Jenny Robles to Tom Varavaro-Re: Ryan and Mark		
164	Email from PCI to M. Morris		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
165*	1/13/17 email from M. Morris to E. Marcotulli, R. Dellinger, L. Guarente		
166	Email from M. Morris to C. Donovan		
167	Email from PCI to M. Morris		
168	PDF titled "Document Approval; Method Qualification Protocol - (AM-C_QC-1170) Assay and Purity Determination of Nicotinamide Riboside Chloride by HPLC-CAD"		
169	Email from D. Alminana to E. Morris and D. Magida		
170	Email from D. Alminana to PCI, M. Morris and D. Magida		
171	Email from D. Aliminana to D. Magida and M. Morris		
172	Email with attachment from M. Morris to PCI and D. Alminana		
173	Email from M. Morris to AMPAC		
174	Email with attachments from M. Morris to L. Brown and W. Rowe		
175	Email from W. Christopher to D. Alminana, C. Castro, E. Marcotulli and L. Guarente		
176*	Interview with L. Guarente, dated 4/14/15		
177	Email with attachment from D. Magida to A. Hoover		
178	Excel titled "Inventory Smmary - Elysium Health_1.04.18_xlsx Raw Materials"		
179	Excel titled "Inventory Smmary - Elysium Health_1.04.18_xlsx Unit Economic Cost"		
180	Excel titled "Inventory Smmary - Elysium Health_1.04.18_xlsx Basis Lots"		
181	Native Excel file (Elysium financial projections)		
182	PDF titled "BVA - Elysium 409a Valuation Report FINAL 6.27.2018"		
183	Letter sent via email from Julia Nahigian (former counsel for Elysium) to Barrett Anderson (counsel for ChromaDex) on August 10, 2018		
184	Letter sent via email from Michael Powell (former counsel for Elysium) to Barrett Anderson (counsel for ChromaDex) on August 10, 2018		
185	Excel titled "Dan Alminana iPhone7_A1661_Report"		
186	Excel titled "Dan Alminana iPhoneSE_A1662_Report"		
187	Excel titled "Eric_Marcotulli_iPhone6_A1549_Report"		
188	Mark Morris's Responses and Objections to ChromaDex's First Set of Interrogatories, dated January 7, 2019.		
189	Acknowledgment page from final deposition of Eric Marcotulli		
190	Errata for March 27, 2019 Deposition of Eric Marcotulli		
191	Opening Expert Report of Lance Gunderson		
192	Rebuttal and Supplemental Expert Report of Lance Gunderson		
193	Acknowledgment page from final deposition of Daniel Alminana		
194	Errata for March 29, 2019 Deposition of Daniel Alminana		
195	Declaration of Mark Morris in Support of Defendants' Motion for Partial Summary Judgment, filed August 16, 2019 (Dkt. 234-1)		
196	Declaration of Daniel Alminana, filed Dec. 11, 2020 (Dkt. 455-2)		
197	Declaration of Eric Marcotulli, filed Dec. 11, 2020 (Dkt. 455-1)		
198	Excel titled "Inventory Forecast.xlsx Forecast"		
199	Excel titled "02.2016, 2017, 2018 Elysium Health Financials"		
200	Excel titled "Inventory Summary 2019."		
201	https://www.elysiumhealth.com/en-us/science		
202	https://www.elysiumhealth.com/en-us/plans-pricing		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
203	https://www.elysiumhealth.com/en-us/basis		
204	All Pleadings		
205	All Discovery Requests and Responses		
206	Sample of NIAGEN		
500	Email with attachments from D. Alminana to F. Jaksch and E. Marcotulli		
501	Email with attachments from M. Morris to M. Clemens, J. Golder, Z. Mendez and T. Rhonemus		
502	Email from M. Morris to E. Marcotulli, R. Dellinger, D. Alminana		
503	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
504	Email with attachments from E. Swick to R. Fried, T. Varvaro, F. Jaksch, T. Klinghoffer and H. Van Blarcom		
505	Email with attachments from Dan Alminana to F. Jaksch, J. Lee, T. Varvaro, E. Marcotulli and M. Morris		
506	Email with attachments from C. Villalobos to F. Jaksch		
507	Email from T. Rhonemus to B. Reynolds		
508	Email from B. Reynolds to T. Rhonemus		
509	Email with attachments from Dan Alminana to F. Jaksch, C. Villalobos, D. Alminana, E. Marcotulli, M. Morris, T. Varvaro, T. Rhonemus and W. Black		
510	Excel titled "NR Ingredient Sales Data for all customer"		
511	Email with attachments from D. Magida to D. Alminana		
512	Email from D. Alminana to T. Varvaro, E. Marcotulli, F. Jaksch and T. Rhonemus		
513	Email with attachments from W. Black to T. Varvaro, T. Rhonemus, F. Jaksch		
514	Email from T. Rhonemus to A. Beninati, B. Reynolds and T. Varvaro		
515	Email from T. Rhonemus to A. Beninati, A. Reynolds, T. Varvaro and H. Van Blarcom		
516	Email with attachments from to D. Alminana, E. Marcotulli and S. Block		
517	Email with attachments from T. Blaser to T. Varvaro and T. Rhonemus		
518	Email from T. Varvaro to T. Blaser		
519	PDF titled "Nectar7 David D'Arcangelo Inventory Purchase Letter 6.22.2017"		
520	Email from D. Alminana to E. Marcotulli		
521	PDF titled "Amendment to Supply Agreement"		
522	Email from D. Alminana to F. Jaksch, T. Rhonemus, T. Varvaro, M. Morris, C. Villalobos, E. Marcotulli		
523	Email from J. Lee to T. Varvaro		
524	Email from F. Jaksch to J. Lee, T. Varvaro		
525	Email with attachment from W. Black to T. Varvaro, T. Rhonemus, F. Jaksch		
526	Email from T. Varvaro to W. Black, T. Varvaro, F. Jaksch and T. Rhonemus		
527	Email from B. Reynolds to D. Alminana, L. Guarente and E. Marcotulli		
528	Opening Expert Report of Lance Gunderson		
529	Rebuttal and Supplemental Expert Report of Lance Gunderson		
530	Opening Expert Report of Iain Cockburn & Exhibits		
531	Rebuttal Expert Report of Iain Cockburn		
532	ChromaDex's 2nd Supplemental and Supplemental Responses to Elysium Health, Inc.'s First Set of Interrogatories		
533	Excel Spreadsheet		
534	Email from Frank Jaksch to Collene Villalobos-re-LIEF PO Number 55655		
535	Email from Frank Jaksch to Dan Alminana-Re-Wired Magazine and NR Questions		
536	E-mail from Leonard Guarente to Robert Fried-Re-Introduction		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
537	E-mail from Frank Jaksch to Dan Alminana-Re-Call today or tomorrow		
538	E-mail from Frank Jaksch to Stephen Block-Elysium Health Supply Agreement 2- 3-2014		
539	E-mail from F.Jaksch to Stephen Block-Re-FW-Call and Royalty Report		
540	Email from Frank Jaksch to Stephen Block-Re-FW-Call and Royalty Report		
541	Email from Frank Jaksch to Stephen Block-Re-FW-Call and Royalty Report		
542	E-mail from Frank Jaksch to Stephen Block-FW Follow-up		
543	E-mail from Frank Jaksch to Stephen Block-FW Follow-up		
544	E-mail from Frank Jaksch to Stephen Block-Re-FW Letters Regarding Breaches		
545	E-mail from Frank Jaksch to Dan Alminana; Stephen Block-Re-Discussion		
546	E-mail from Stephen Block to Robert Fried-Re-Proposal		
547	E-mail to Jeff Baxer; Steve Allen; Stephen Block; Robert Fried; Kurt Gustafson-Re-CDXC DTC Channel Development: Discussion Paper		
548	E-mail from Frank Jaksch to Stephen Block; Steve Allen-Re-First Draft of terms for HS agreement		
549	Spreadsheet Text Messages (including native)		
550	E-mail to Jeff Baxer; Kurt Gustafson; Robert Fried; Steve Allen; Stephen Block-Re-Options		
551	E-mail from Stephen Block to Robert Fried-Re-Term Sheet		
552	E-mail from Robert Fried to Stephen Block-Re-Term Sheet		
553	Email from Stephen Block to Robert Fried-Re-Transaction Term Sheet		
554	Email from Stephen Block to Tom Varvaro-Re-Fwd: Potential Aquisition of Healthspan and Employment of Robert Fried		
555	E-mail from Tom Varvaro to Stephen Block-Re-Potential Acquisition of Healthspan and Employment of Robert Fried		
556	E-mail from Stephen Block to Tom Varvaro-Re-Potential Acquisition of Healthspan and Employment of Robert Fried		
557	E-mail from Tom Varvaro to Frank Jaksch; Stephen Block; Steve Allen; Jeff Baxter; Kurt Gustafson; Robert Fried Re-FW Valuation Draft		
558	SEC Form 8-K - ChromaDex Corporation Dated July 9, 2015		
559	E-mail from Michael Brauser to Frank Jaksch-Re-Call		
560	E-mail from Michael Brauser to Dan Alminana-Re-Need to Call to reslove issue		
561	Email from Michael Brauser to Barry Honig; John Stetson; Josh O'Rourke-FW: Elysium		
562	E-mail from Michael Brauser to Geoffery Harrison-Re-(Redacted)		
563	Form 8K for ChromaDex-Date of Report		
564	Exhibit C to CDC Fifth Amended Complaint (Supply Agreement between ChromaDex and Elysium-dated 2-3-2014)		
565	Exhibit D to CDC Fifth Amended Complaint (Amendment to Supply Agreement between ChromaDex and Elysium-dated 2-19-2016		
566	Email from Troy Rhonemus to Dan Alminana-Re-NR+ Ptero Exclusivity-Amendment to Supply Agreement		
567	E-mail from Collene Villalobos to Troy Rhonemus and Frank Jaksch-Re- Fwd: LIEF PO Number 55655		
568	E-mail from Teddy Klinghoffer to Heather Van Blarcom-Re-FW: HealthSpan Research LLC Agreement		
569	E-mail from Heather Van Blarcom to Teddy Klinghoffer-Re- Healthspan Research Insterest Purchase Agreement		
570	E-mail from Heather Van Blarcom to Troy Rhonemus-Re-FW: Executed Documents: Healthspan Research LLC		
571	E-mail from Collene Villalobos to Troy Rhomemus and Will Black-Re-Niagen-MAP Pricing		
572	E-mail from Troy Rhonemus to Frank Jaksch- Attachment-Elysium Health Supply Agreement 2.3.14		
573	E-mail from Frank Jaksch to Troy Rhonemus-NR Supply Agreements Summary for Elysium		
574	E-mail from Troy Rhonemus to Will Black-Re- Niagen and pTeroPure for Elysium		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
575	E-mail sent to Troy Rhonemus-Re-2017 Sales and Marketing Budget		
576	SEC Form 8K for ChromaDex Corporation		
577	SEC Filing-Form-for ChromaDex Corporation-Schedule 14A		
578	SEC Form 8K for ChromaDex Corporation		
579	SEC Form 10-Q-ChromaDex Corporation-for the quarterly period ended September 30, 2017		
580	SEC Form 8K for ChromaDex Corporation		
581	E-mail from Erin Swick to Heather Van Blarcom-Re- #36995134v6 Active -BPI Sports-Supply Agreement ChromaDex cdx comments		
582	E-mail from Barry Kaufman to Tom Varvaro-Re-W-Deren-Lewis v. ChromaDex/Jaksch, et al		
583	E-mail from James Lee to Tom Varvaro-Re-Elysium-New Order		
584	E-mail from Eric Marcotulli to Mark Morris and Dan Alminana-Re-Purchase Orders		
585	E-mail from Collene Villalobos to Tom Varvaro-Re-Elysium Payment Terms		
586	E-mail from Tom Varvaro to H. Van Blarcom-Draft term sheet		
587	E-mail from Tom Varvaro to Frank Jaksch-Re-Rob Fried Supply Agreement		
588	E-mail from Tom Varvaro to Erin Swick		
589	E-mail from Troy Rhonemus to Tom Varvaro-Re-FW-Exxecuted Documents: Healthspan Research LLC		
590	E-mail from Tom Varvaro to Frank Jaksch-Attachment-Healthspan Research Supply Agreement 8-27-2015		
591	E-mail from Tom Varvaro to Frank Jaksch-Re-FW: Healthspan Memo		
592	E-mail from Tom Varvaro to Frank Jaksch-Re-FW-Rob F.		
593	E-mail from Stephen Block to Steve Allen; Jeff Baxer; Kurt Gustafson-Re-Potential Acquisition of Healthspan and Employment of Rob Fried		
594	E-mail from Stephen Block to Tom Varvaro-Re- Fwd: Potential Acquisition of Healthspan and Employment of Rob Fried		
595	E-mail from Tom Varvaro to James Lee-Re-FW: Potential Acquisition of Healthspan and Employment of Rob Fried		
596	E-mail from M. Robbins to Frank Jaksch and Tom Varvaro-Re-Executed Healthspan Documents		
597	E-mail from Tom Varvaro to Frank Jaksch; Stephen Block; Steve Allen; Jeff Baxer; Kurt Gustafson and Robert Fried-Re FW-Valuation Draft		
598	Email from Frank Jaksch to Andrew Johnson-Re- FW-ICR's input on our Customer Talking Points		
599	E-mail from James Lee to Tom Varvaro-Re-Memo-Healthspan Acquisition Accounting Treatment		
600	E-mail from James Lee to Dave Horin and Philip Hood-Re-Accounting Treatment-Asset Purchase		
601	E-mail from Tom Varvaro to James Lee-Re- Valuation Draft		
602	E-mail from Tom Varvaro to Will Black and Andrew Johnson-Re-FW-Valuation Draft		
603	E-mail from James Lee to Tom Varvaro-Re-Royaltys		
604	E-mail from Tom Varvaro to Troy Rhonemus-Re- Book1.xlsx		
605	E-mail from Tom Varvaro to James Lee-Re- FW: 2017 Budget		
606	E-mail from Tom Varvaro to Troy Rhonemus-FW-Niagen License Agreement		
607	E-mail from Tom Varvaro to James Lee-Re- Q2 2017 NR Royalties to Universities		
608	E-mail from James Lee to Tom Varvaro-Re-Elysium Pricing		
609	6-20-2016-E-mail from Frank Jaksch to Andrew Johnson and Tom Varvaro-Re-PR Response		
610	6-24-2016-E-mail from Frank Jaksch to Stephen Block and Tom Varvaro-Re-8-K Logistics and Timing		
611	6-24-2016-E-mail fro Stephen Block ot Frank Jaksch-Re-8-K Logistics and Timing		
612	11-9-2013 E-mail from Frank Jaksch to Tom Varvaro-Fwd: Partnership Agreement-Draft		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
613	4-2-2016- For the quarterly period ended- SEC From 10-Q-ChromaDex Corporation		
614	9-16-2016-E-mail from Paul Jacobson to Will Black; Frank Jaksch and Troy Rhonemus-Re-Comment on the note and our conversation		
615	9-4-2015 E-mail from Frank Jaksch to Tom Varvaro; Troy Rhonemus and Mark Morris-Re-Fwd: The idea of a lifetime-and he blew it		
616	6-30-2016-E-mail from Will Black to Will Black; Frank Jaksch-Re-Elysium Draft		
617	12-7-2016-E-mail from Michael Brauser to F. Carreras (General Catlayst)-Re-Elysium		
618	4-23-2015 Email from Tom Varvaro to Frank Jaksch- Re- Draft Term Sheet		
619	5-4-2015-E-mail from Tom Varvaro to Frank Jaksch-Re- Draft term sheet		
620	11-20-2016-E-mail from Stephen Block to Frank Jaksch-Re- HS Document		
621	12-10-2016-E-mail from Stephen Block to Frank Jaksch-Re-Fwd; Healthspan Acquisition/Rob Fried Employment		
622	12-10-2016-E-mail from Stephen Block to Frank Jaksch-Re- Fwd: Healthspan Acquisition/Rob Fried Employment		
623	3-27-2017-Email from James Lee to N. Marckwordt-Re- ChromaDex-New Share Issuance		
624	12-27-2016-E-mail from Natalie Mikolich to Frank Jaksch and Will Black-Re- Quick Questions from Tech Crunch		
625	12-8-2017-ChromaDex Press Release-NR shown to Improve Mitochondrial Energy Production and Memory in Alzheimer's Disease Research		
626	SEC Form 6-K-Tiger Media, Inc.		
627	4-24-2015-E-mail from Frank Jaksch to Robert Fried-Re-Draft term sheet		
628	6-11-2015-E-mail from Dan Alminanato Rob F.-Re: Checking In		
629	1-5-2016-E-mail from Charles Brenner to Robert Fried-Re-Fwd: Annual Conflict of Interest Disclosure Requirement		
630	1-6-2016-E-mail from Rob F. to Cheryl Romano; Rachel Farabaugh, Charmaine Lacewell; Patrick Thona-Re Fw: Label		
631	1-21-2016-E-mail from Robert Fried to rob@spiritclips.com-Re- Fw: Amendment to the Agreement		
632	1-18-2016-E-mail from Charles Brenner to Robert Fried-Fwd: Healthspan Website Copy for Review		
633	1-24-2016-E-mail from Cheryl Romano to Robert Fried-Re-Fwd: Healthspan Website Copy for Review		
634	1-24-2016-E-mail from Charles Brenner to Robert Fried-Re-Healthspan Website Copy for Review		
635	2-7-2016-E-mail from Charles Brenner to Robert Fried-Re-Healthspan Research agreement		
636	7-31-2015 to 10-23-2017- Text Messages between Robert Fried and Frank Jaksch; Charles Brenner; Rudy Tanzi, Tom Coll. Yvette Holm; Sarah Goodchild; Straus Zelnick. Steve Allen; Jeff Baxer; Nicholas Kotsikos; Rob Levitan; Jeff Sechrest; Jeffery Allen and Steve Rubin		
637	8-6-2016-E-mail from Charles Brenner to Robert Fried-Re- What does healthspan mean?		
638	11-19-2016-E-mail from Frank Jaksch to Robert Fried-Re-Draft term sheet		
639	11-21-2016-E-mail from J. Sechrest to r Robert Fried-Re-Cornerstones for Agreement with Healthspan 1118 2016		
640	11-20-2016-E-mail from Frank Jaksch to Jeff Baxer; Steve Allen; Stephen Block; Robert Fried and Kurt Gustafson-Re-CDXC DTC Channel Development: Discussion Paper		
641	11-22-2016-E-mail from Frank Jaksch to Jeff Baxer; Kurt Gustafson; Robert Fried; Steve Allen; Stephen Block-Re-Options		
642	4-8-2017-E-mail from Troy Rhonemus to Robert Fried; Frank Jaksch; Tom Varvaro-Re-Data		
643	8-11-2017-E-mail from Frank Jaksch to Robert Fried-Re- (none)		
644	11-30-2016-E-mail from Robert Fried to Frank Jaksch-Re: Fwd: NYC next week		
645	7-31-2017-E-mail from N. Mikolich to Frank Jaksch; Robert Fried- Re- Latest Elysium article		
646	8-3-2017-E-mail from Frank Jaksch; Robert Fried-Re-Elysium Picture		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
647	8-9-2017-E-mail from Breah Ostendorf to Robert Fried; Will Black; Andrew Johnson; Frank Jaksch-Re- Elysium activity summary		
648	9-5-2017-E-mail from Breah Ostendorf to Frank Jaksch; Robert Fried; Andrew Johnson; Amy Boileau-Re- Toulene PR (002)		
649	6-29-2016-E-mail from Frank Jaksch to Will Black-Re-FW: Wired Magazine and NR Questions		
650	8-16-2016-E-mail from Tom Varvaro to Will Black-Re-FW: Call and Royalty Report		
651	8-16-2016-E-mail from Troy Rhonemus to Will Black-Re-Call and Royalty report		
652	8-2-1016-E-mail from Frank Jaksch to Will Black-Re-Call and Royalty Report		
653	9-21-2016-E-mail from John Mai to Will Black-Re-Niagen pricing		
654	10-11-2016-E-mail from Will Black to E. Somer-Re-ChromaDex news		
655	9-8-2016-E-mail from Headley Lee to Will Black; Kevin Suarez-Re-Call to discuss product launch		
656	9-15-2016-E-mail from Will Black to Paul Jacobson		
657	9-16-2016-E-mail from Will Black to Paul Jacobson-Re-comment on the note and our conversation		
658	9-23-2016-E-mail from Will Black to Glenn MacEachern-Re-Follow-up to our discussion this morning		
659	11-17-2016-E-mail from Will Black to Frank Jaksch-Re-Agreement outline-Rob Fried		
660	11-18-2016-E-mail from Will Black to Frank Jaksch-Re- Rob Draft		
661	12-19-2016-E-mail from Will Black to Troy Rhonemus-Re DTC Customer analysis		
662	12-19-2016-E-mail from Will Black to Tom Varvaro; Troy Rhonemus-Re-DRC customer contribution to CDX		
663	1-13-2017-E-mail from Will Black to Frank Jaksch-Re-FW: Sales Budget		
664	1-17-2017-E-mail from Will Black to Tom Varvaro-Re-2017 Budget		
665	7-11-2017-E-mail from Brian Park to Will Black-Re- NIAGEN-Korea		
666	4-8-2017-E-mail from Troy Rhonemus to Robert Fried, Frank Jaksch, Tom Varvaro-Re- Data		
667	GRAS Notices-GRN No. 635- Date of Filing- March 29, 2016-Substance-Nicorinamide Riboside Chloride		
668	10-3-2015 SEC-Form 10-Q- ChromaDex Corporation		
669	Email from Dan Alminana to Frank Jaksch, copying Leonard Guarente, Bob Prag, Eric Marcotulli, and Laura Carney, sent August 27, 2013		
670	Text message sent by Frank Jaksch to Will McCamy		
671	Form 8-K filed with the U.S. Securities & Exchange Commission ("SEC") by ChromaDex		
672	Text message sent by Robert Fried to Dan Levitan		
673	Form 10-K filed by ChromaDex with the SEC for the fiscal year ending December 30, 2017		
674	ChromaDex's Answer and Counterclaims Against Novex Biotech LLC, filed on May 24, 2019 in the litigation captioned Novex Biotech, LLC v. ChromaDex, Inc., Case No. 2:19-cv-00271- JNP-PMW (D. Utah) (ECF No. 26)		
675	Native Excel file (NR Sales, Profits, Costs and Inventory Levels)		
676	Email and attachments from Dan Alminana to Frank Jaksch, copying Eric Marcotulli		
677	Email and attachments from Dan Alminana to Collene Villalobos, copying Frank Jaksch, Mark Morris, and Eric Marcotulli, sent February 10, 2015		
678	Email and attachments from Dan Alminana to Frank Jaksch, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent May 27, 2015		
679	Email and attachments from Dan Alminana to Frank Jaksch, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent July 2, 2015		
680	Email and attachments from Dan Alminana to Frank Jaksch, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent October 2, 2015		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
681	Email and attachments from Dan Alminana to Frank Jaksch, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent November 5, 2015		
682	Email and attachments from Dan Alminana to Frank Jaksch, Troy Rhonemus, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent February 22, 2016		
683	Email and attachments from Dan Alminana to Frank Jaksch, Troy Rhonemus, Tom Varvaro, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent April 1, 2016		
684	Email from Dan Alminana to Frank Jaksch, copying Eric Marcotulli, sent May 30, 2016		
685	Email from Dan Alminana to Frank Jaksch, copying Eric Marcotulli, sent June 13, 2016		
686	Email and attachments from Dan Alminana to Frank Jaksch, Troy Rhonemus, Tom Varvaro, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent June 28, 2016		
687	Email from Frank Jaksch to Dan Alminana, copying Troy Rhonemus, Tom Varvaro, Mark Morris, Collene Villalobos, Eric Marcotulli, and Will Black		
688	Email from Frank Jaksch to Dan Alminana, copying Troy Rhonemus, Tom Varvaro, Mark Morris, Collene Villalobos, Eric Marcotulli, and Will Black		
689	Email from Will Black to Dan Alminana		
690	Form 8-K filed by ChromaDex with the SEC on July 9, 2013		
691	Email and attachments from Tom Varvaro to Dan Alminana, Eric Marcotulli, copying Frank Jaksch, Troy Rhonemus, and Will Black, sent September 8, 2016		
692	Email and attachment from Daniel Magida to Dan Alminana, sent June 24, 2016		
693	“Generally Recognized As Safe (GRAS) Determination for Niagen (Nicotinamide Riboside Chloride)” filed by ChromaDex, publicly available at https://www.fda.gov/files/food/published/GRAS-Notice-000635--Nicotinamide-ribose-ribose-chloride.pdf		
694	Email and attachment from Troy Rhonemus to Frank Jaksch, sent May 22, 2017,		
695	Email and attachment from Mark Morris to Sean Torbati, sent June 10, 2013		
696	Email and attachment from Katie Lowerison to Mark Morris, sent October 10, 2013		
697	Email from Eric Marcotulli to Frank Jaksch, copying Dan Alminana		
698	Email and attachment from Mark Morris to Troy Rhonemus, dated August 27, 2015		
699	Email and attachment from Jenny Schwanky to Timothy O’Brien, copying Edward Schauder, Tom Varvaro and Frank Jaksch, sent July 12, 2013		
700	Email and attachment from Fran Jaksch to Hugh Dunkerley, Jeff, Baxter, Reid Dabney, Rob Fried, Steve Allen, Steve Block and Tom Varvaro, sent on March 16, 2016		
701	Email and attachment from Frank Jaksch to Karin Writes, sent June 25, 2016		
702	Email and attachments from James Lee to Mark Morris, copying Troy Rhonemus, sent April 28, 2015 (Elysium Health Niagen Royalty Report, Q3 2014)		
703	Email and attachment from Dan Alminana to James Lee and Tom Varvaro, copying Frank Jaksch, Mark Morris, Eric Marcotulli, sent June 17, 2015 (Elysium Health Niagen Royalty Report Q12015)		
704	Email and attachment from Dan Alminana to James Lee, Tom Varvaro, copying Frank Jaksch, Mark Morris and Eric Marcotulli, sent December 17, 2015 (Elysium Health Niagen Royalty Report Q3 2015)		
705	Email and attachment from Dan Alminana to James Lee, Tom Varvaro, copying Frank Jaksch, Troy Rhonemus, and Mark Morris, sent March 23, 2016 (Elysium Health Niagen Royalty Report Q4 2015)		
706	Email and attachment from James Lee to Dan Alminana, Frank Jaksch, Tom Varvaro, Troy Rhonemus and Mark Morris, copying Eric Alminana (Elysium Health Niagen Royalty Report Q2 2016)		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
707	Letter from Will Black to Headley Lee		
708	Email and attachments from Frank Jaksch to Giles Parisot		
709	Email and attachment from Will Black to Kartik Chandrasekara		
710	Document titled Where to Buy Niagen		
711	Email from Reto Rieder to John Mai		
712	Email from Dan Alminana to Will Black, copying Eric Marcotulli, Troy Rhonemus, Frank Jaksch, and Tom Varvaro, sent August 20, 2016		
713	Email chain between Eric Marcotulli, Frank Jaksch, Dan Alminana, Leonard Guarente, Bob Prag RE: Follow-Up: Summary Terms with attachment EH/CDXC Partnership Proposal		
714	Email chain between Frank Jaksch, Dan Alminana, Eric Marcotulli, Leonard Guarente, Bob Prag RE: Follow-up: Summary Terms with attachment ChromaDex Elysium Niagen Draft Term Sheet		
715	ChromaDex Form 8-K		
716	ChromaDex Form 10-K (CERTIFIED) 2018		
717	ChromaDex Form 10-K 2018		
718	ChromaDex Form 10-K (CERTIFIED) 2017		
719	ChromaDex Form 10-K 2017		
720	ChromaDex Form 10-Q (CERTIFIED)		
721	ChromaDex Form 10-Q		
722	ChromaDex Form 10-Q		
723	ChromaDex Form 8-K (CERTIFIED)		
724	ChromaDex Form 8-K (CERTIFIED)		
725	ChromaDex Form 8-K (CERTIFIED)		
726	ChromaDex Form 10-Q (CERTIFIED)		
727	ChromaDex Form 10-Q (CERTIFIED)		
728	ChromaDex Form 10-Q		
729	ChromaDex Form 10-K (CERTIFIED)		
730	ChromaDex Form 10-K (CERTIFIED)		
731	Certified copy of March 201810-Q		
732	Niagen Branding Bottle Photographs		
733	ChromaDex Form 10-K		
734	ChromaDex Form 10-Q		
735	Manufacturing and Supply Agreement Between ChromaDex and W.R. Grace & Co.-Conn		
736	ChromaDex Form 10-K (1/3/2015)		
737	Email from Tom Varvaro to M. Tillotson Cc: Z. Nigent, K. Sabin RE: Valuation with attachments Delaware Certificate of Formation of HealthSpan Research LLC; ChromaDex Meeting February 10, 2017 Presentation; Letter from Scalar to Tom Varvaro re: Engagement for Valuation Services, March 3, 2017; HealthSpan Balance Sheet		
738	Letter from GRACE to ChromaDex RE: Take or Pay Purchase Agreement for Nicotinamide Riboside Chloride		
739	ChromaDex Form 8-K		
740	Email from Ryan Dellinger to Claire Kruger, Dietrich Conze, Juan Crespo-Barreto, copying Troy Rhonemus		
741	Manufacturing and Supply Agreement Between ChromaDex and W.R. Grace & Co.-Conn		
742	Email from Troy Rhonemus to Brett Reynolds		
743	Emial from Troy Rhonemus to Brett Reynolds, copying Audrey Kelleman		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
744	Email from Troy Rhonemus to Brett Reynolds		
745	ChromaDex 10-K for fiscal year ended December 31, 2016		
746	ChromaDex Form 10-K (2016)		
747	ChromaDex Form 10-K (2017)		
748	http://d18rn0p25nwr6d.cloudfront.net/CI-K-0001386570/bb257127-d60c-433d-9a5a-712898864580.pdf .		
749	https://www.lifeextension.com/magazine/2014/11/the-youth-restoring-benefits-of-nad/page-01?p=1 .		
750	Email from Mark Morris to Erica K. Bullard		
751	Email from Mark Clemens to Mark Morris, copying Josh Golder and Zaid Mendez		
752	Email from Mark Morris to Arjun Avila		
753	Email and attachment from Mark Morris to Adina Mayerhoff		
754	Email and attachment from Mark Morris to Debbie Grossblat, copying Aaron Biesbrock, Tomohiro Hakozaiki, John Oblong, Jesus Velazquez, Carl Margraf, Heather Rocchetta, James Dunbar, John French, and Troy Rhoenmus		
755	Email and attachments from Mark Morris to Shawn Wells		
756	Email from Mark Morris to Shawn Wells		
757	Email from Mark Morris to Arjun Avila		
758	Email from Mark Morris to Josh Golder		
759	Email from Mark Morris to le-brandon@robinsonpharma.com, copying Mina Kami		
760	Email and attachment from James Lee to Tom Varvaro		
761	Email and attachment from Tom Varvaro to James Lee		
762	Elysium Employment Offer Letter to Mark Morris		
763	PDF titled "Opko Health: The Placebo Effect"		
764	Email from D. Alminana to F. Jaksch and E. Marcotulli		
765	Email from D. Alminana to F. Jaksch and E. Marcotulli		
766	Email from E. Marcotulli to R. Nelson		
767	Email from E. Marcotulli to S. Baum		
768	Email from S. Block to T. Varvaro and F. Jaksch		
769	Email from S. Block to F. Jaksch		
770	Email from E. Marcotulli to R. Nelson and J. McDonnell		
771	Email from M. Morris to D. Alminana and E. Marcotulli		
772	Opinion in Jaksch v. Seitz Family Partnership, L.P., 2008 WL 2352494		
773	Email with attachment from D. Alminana to W. Black, E. Marcotulli, F. Jaksch, T. Rhonemus, T. Varvaro		
774	Seeking Alpha Article re Chanticleer Holdings Stock Fall		
775	Seeking Alpha Article re IDI Strong Sell on Fraud Lawsuits		
776	PDF titled IDI Responds to Anonymous Blog Post After 50% Selloff		
777	Smashmouth Investigative Journalism Article re Microcap Attorney Jaclin's Co-Conspirator Turned DOJ Witness in Shell Factory Scheme		
778	PDF titled ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, Williams Smithburg, to its Board of Directors		
779	Bleeker Street Research Article re Pershing Gold and ChromaDex Exposed		
780	SEC Form 8-K, dated June 20, 2016		
781	Smashmouth Investigative Journalism Article re Investor Barry Honig Subject of SEC MGT Capital Subpoena		
782	ShareSleuth Article re Stealth promotion network linked to more pump and dump schemes		

ChromaDex, Inc. v. Elysium Health, Inc. et al.
Case No. 8:16-cv-02277-CJC-DFM
Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Description	Date Identified	Date Admitted
783	Email from E. Marcotulli to D. Alminana		
784	Email from F. Jaksch to E. Marcotulli and D. Alminana		
785	Email from B. Koshy to D. Magida and M. Rosa		
786	Email from M. Morris to D. Alminana		
787	Email from M. Morris to D. Alminana		
788	Email from M. Morris to A. Charrette		
789	Email and attachments from F. Jaksch to R. Kornberg		
790	Email and attachments from F. Jaksch to M. Schwehn, T. Goyne, and K. Jantzi		
791	Email and attachments from F. Jaksch to A. Allen and B. Kim		
792	Email and attachments from F. Jaksch to E. Eli and G. Brauser		
793	Email and attachments from F. Jaksch to M. Korson		
794	Email and attachments from F. Jaksch to S. Hall, M. Murray, R. Lynch, and L. Kelly		
795	Email and attachments from F. Jaksch to J. Wallace and B. Prag		
796	Email and attachments from M. Morris to S. Durkee		
797	Email and attachments from M. Morris to G. Bruno		
798	Email and attachments from M. Morris to J. Janssen		
799	Email and attachments from M. Morris to E. Grinblat		
800	Email and attachments from M. Morris to M. Galler		
801	Email and attachments from M. Morris to M. Brown		
802	Email and attachments from M. Morris to J. Sullivan		
803	Email and attachments from M. Morris to S. Peterson		
804	Email and attachments from M. Morris to B. Andersen		
805	Email and attachments from F. Jaksch to M. LeDoux, D. Reine, D. Jan, and L. Guzman		
806	Email and attachments from F. Jaksch to J. Peniche		
807	Email and attachments from M. Morris to J. Del Favero		
808	Email and attachments from F. Jaksch to R. Firger		
809	Email and attachments from T. Varvaro to C. Norman and J. Becker		
810	SEC Form 8-k		
811	Email from M. Morris to M. Perez and C. Villalobos		
812	Sample of Basis		
813	SEC Form 10-Q-ChromaDex Corporation-for the quarterly period ended June 30, 2021		
814	SEC Form 10-Q-ChromaDex Corporation-for the quarterly period ended March 31, 2021		
815	SEC Form 10-K-ChromaDex Corporation-for the fiscal year ended December 31, 2020		